Rogers Corp

ROG

Market cap $1.51B

Rogers' third-quarter earnings of $0.90 per share beat analyst expectations of $0.69 by a wide margin. Industrial, electric vehicle, and aerospace segments drove double-digit sales growth for the engineered materials company.

Rogers Corporation ( ROG ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Stephen Haymore - Director of Investor Relations Ali El-Haj - Interim President & Interim CEO Laura Russell - CFO, Senior VP & Treasurer Conference Call Participants Dan Moore - CJS Securities, Inc. Craig Ellis - B. Riley Securities, Inc., Research Division David Silver Presentation Operator Good afternoon.

Rogers Corp. (ROG) came out with quarterly earnings of $0.9 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.98 per share a year ago.

CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) today announced financial results for the third quarter of 2025. "Third quarter results were at the upper end of guidance due to improved end-market demand and good execution on cost improvement initiatives,” stated Ali El-Haj, Rogers' Interim President and CEO. "Compared to the prior quarter sales, gross margin, earnings, adjusted EBITDA and free cash flow all showed substantial improvement." "Fourth quarter sales and earnings are.

Roche Holding AG (OTCQX:RHHBY) Q3 2025 Sales Call October 23, 2025 8:00 AM EDT Company Participants Thomas Schinecker - Group Chief Executive Officer Alan Hippe - Chief Financial Officer Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Matthew Sause - Chief Executive Officer Bruno Eschli - Head of Investor Relations Conference Call Participants Richard Vosser - JPMorgan Chase & Co, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Michael Leuchten - Jefferies LLC, Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Sachin Jain - BofA Securities, Research Division Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas Exane, Research Division Sarita Kapila - Morgan Stanley, Research Division Steve Scala - TD Cowen, Research Division Yihan Li - Barclays Bank PLC, Research Division Presentation Operator [indiscernible] webinar 2025.

Roche Holding AG (OTCQX:RHHBY) Shareholder/Analyst Call October 21, 2025 11:00 AM EDT Company Participants Bruno Eschli - Head of Investor Relations Nilesh Mehta - Global Franchise Head - Ophthalmology Chris Brittain - Global Head of Ophthalmology Product Development & VP Conference Call Participants Nisha Acharya César Briceño Michael Leuchten - Jefferies LLC, Research Division Peter Verdult - BNP Paribas Exane, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Steve Scala - TD Cowen, Research Division Matthew Weston - UBS Investment Bank, Research Division Presentation Operator My name is Henrik, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded.

CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE: ROG) (the “Company”) today announced that Peter Wallace, Chair of the Board of Directors (the “Board”), has informed the Board of his decision not to stand for re-election at the Company's 2026 Annual Meeting of Shareholders. In anticipation of this transition, the Board has elected Armand Lauzon, an existing member of the Board since 2023, to serve as the next Chair, effective immediately. Mr. Wallace will partner with Mr. Lauzon over.

CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce third quarter 2025 results on October 29, 2025 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Ali El-Haj, Interim President and Chief Executive Officer, who will be joined by Laura Russell, Senior Vice President and Chief Financial Officer. A live webcast of the event and related slide presentation can be accessed on Rogers' Investor Relations w.

CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.

Roche Holding AG - Special Call Company Participants Bruno Eschli - Head of Investor Relations Teresa Graham - Chief Executive Officer of Roche Pharmaceuticals Levi Garraway - Executive VP, Head of Global Product Development & Chief Medical Officer Charles Fuchs - Global Head of Oncology & Hematology Drug Development - Genentech & Roche Hideki Garren Larry Tsai Chris Brittain - Global Head of Ophthalmology Product Development & VP Manu Chakravarthy Conference Call Participants Richard Vosser - JPMorgan Chase & Co, Research Division Sachin Jain - BofA Securities, Research Division Matthew Weston - UBS Investment Bank, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Michael Leuchten - Jefferies LLC, Research Division Sarita Kapila - Morgan Stanley, Research Division Emmanuel Papadakis - Deutsche Bank AG, Research Division Naresh Chouhan - Intron Health Advisors Ltd Justin Steven Smith - Sanford C.